Literature DB >> 10328110

Possible role of calponin h1 as a tumor suppressor in human uterine leiomyosarcoma.

A Horiuchi1, T Nikaido, S Taniguchi, S Fujii.   

Abstract

BACKGROUND: Calponin h1, a basic actin-binding protein capable of inhibiting smooth muscle contraction, is a constitutive element of smooth muscle cells. However, in leiomyosarcoma (a type of smooth muscle neoplasm of the uterus), reduced expression of calponin h1 is observed, as we have reported previously. In this study, we sought to assess the effects (in vitro and in vivo) of increasing calponin h1 expression in leiomyosarcoma cells.
METHODS: A plasmid containing a human calponin h1 complementary DNA and a bacterial neomycin-resistance gene was transfected into the human leiomyosarcoma cell lines SKN and SK-LMS-1 by electroporation. Southern blotting, reverse transcription-polymerase chain reaction analysis, western blotting, and immunohistochemistry were used to confirm DNA transfer and expression of the calponin h1 protein in neomycin-resistant clones. We characterized the morphology of calponin h1-transfected cells, and we evaluated their proliferative activity and tumorigenicity by use of a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide assay, an anchorage-independent growth assay, and a nude mouse tumorigenicity assay.
RESULTS: The morphology of calponin h1-transfected cells in culture resembled that of cultured normal myometrial smooth muscle cells. With SK-LMS-1 cells, proliferation of calponin h1-transfection cells was reduced to 69% of control; with SKN cells, calponin h1 transfection reduced proliferation to 70% of control. In assays of anchorage-independent growth and in vivo tumorigenicity, both growth and tumorigenicity were statistically significantly reduced in calponin h1-transfected leiomyosarcoma cells.
CONCLUSIONS: Calponin h1 may function as a tumor suppressor in leiomyosarcoma. Clinically, transfer of a calponin h1 complementary DNA into poorly differentiated leiomyosarcoma cells may be of potential therapeutic value through induction of a normal, differentiated cellular phenotype.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10328110     DOI: 10.1093/jnci/91.9.790

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  16 in total

1.  Frequent expression of smooth muscle markers in malignant fibrous histiocytoma of bone.

Authors:  T Ueda; N Araki; M Mano; A Myoui; S Joyama; S Ishiguro; H Yamamura; K Takahashi; I Kudawara; H Yoshikawa
Journal:  J Clin Pathol       Date:  2002-11       Impact factor: 3.411

2.  Calponin repeats regulate actin filament stability and formation of podosomes in smooth muscle cells.

Authors:  Mario Gimona; Irina Kaverina; Guenter P Resch; Emmanuel Vignal; Gerald Burgstaller
Journal:  Mol Biol Cell       Date:  2003-03-20       Impact factor: 4.138

3.  G-protein-coupled-receptor activation of the smooth muscle calponin gene.

Authors:  N O Dulin; S N Orlov; C M Kitchen; T A Voyno-Yasenetskaya; J M Miano
Journal:  Biochem J       Date:  2001-07-15       Impact factor: 3.857

Review 4.  Smooth muscle signalling pathways in health and disease.

Authors:  H R Kim; S Appel; S Vetterkind; S S Gangopadhyay; K G Morgan
Journal:  J Cell Mol Med       Date:  2008-12       Impact factor: 5.310

Review 5.  Calponin isoforms CNN1, CNN2 and CNN3: Regulators for actin cytoskeleton functions in smooth muscle and non-muscle cells.

Authors:  Rong Liu; J-P Jin
Journal:  Gene       Date:  2016-03-10       Impact factor: 3.688

6.  Overexpression of H1 calponin in osteoblast lineage cells leads to a decrease in bone mass by disrupting osteoblast function and promoting osteoclast formation.

Authors:  Nan Su; Maomao Chen; Siyu Chen; Can Li; Yangli Xie; Ying Zhu; Yaozong Zhang; Ling Zhao; Qifen He; Xiaolan Du; Di Chen; Lin Chen
Journal:  J Bone Miner Res       Date:  2013-03       Impact factor: 6.741

7.  Molecular Approach to Uterine Leiomyosarcoma: LMP2-Deficient Mice as an Animal Model of Spontaneous Uterine Leiomyosarcoma.

Authors:  Takuma Hayashi; Akiko Horiuchi; Kenji Sano; Nobuyoshi Hiraoka; Yae Kanai; Tanri Shiozawa; Susumu Tonegawa; Ikuo Konishi
Journal:  Sarcoma       Date:  2011-03-08

8.  Potential role of LMP2 as tumor-suppressor defines new targets for uterine leiomyosarcoma therapy.

Authors:  Takuma Hayashi; Akiko Horiuchi; Kenji Sano; Nobuyoshi Hiraoka; Mari Kasai; Tomoyuki Ichimura; Tamotsu Sudo; Yoh-Ichi Tagawa; Ryuichiro Nishimura; Osamu Ishiko; Yae Kanai; Nobuo Yaegashi; Hiroyuki Aburatani; Tanri Shiozawa; Ikuo Konishi
Journal:  Sci Rep       Date:  2011-12-05       Impact factor: 4.379

9.  Involvement of proteasome β1i subunit, LMP2, on development of uterin leiomyosarcma.

Authors:  Takuma Hayashi; Akiko Horiuchi; Kenji Sano; Nobuyoshi Hiraoka; Mari Kasai; Tomoyuki Ichimura; Satoru Nagase; Osamu Ishiko; Tanri Shiozawa; Yae Kanai; Nobuo Yaegashi; Hiroyuki Aburatani; Susumu Tonegawa; Ikuo Konishi
Journal:  N Am J Med Sci       Date:  2011-09

10.  Expression pattern and regulation of genes differ between fibroblasts of adhesion and normal human peritoneum.

Authors:  Ujjwal K Rout; Ghassan M Saed; Michael P Diamond
Journal:  Reprod Biol Endocrinol       Date:  2005-01-10       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.